Smoldering multiple myeloma · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Thalidomide monotherapy Variant #03 | — | R 614 268 | 540d | ~23.0 mo | — | ~2 | ~R 1 228 537 PFS proxy · indirect | 1 |
Lenalidomide and Dexamethasone (Rd) Variant #09 | — | R 14 094 | 35d | — | — | — | — | 1 |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | — | — | — | — | 1 |
Melphalan and Prednisone (MP) Variant #18 | — | R 206 | 42d | — | ~29.1 mo | — | — | 2 |
Observation Partial | — | — | — | — | — | — | — | 1 |
5 of 5 regimens shown